Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer

Supplemental Digital Content is available in the text. Objectives: Location of the primary tumor has prognostic value and predicts the effect of certain therapeutics in synchronous metastatic colorectal cancer. We investigated whether the association between primary tumor resection (PTR) and overall survival (OS) also depends on tumor location. Methods: Data on synchronous metastatic colorectal cancer patients from the Netherlands Cancer Registry (n=16,106) and Surveillance, Epidemiology, and End Results (SEER) registry (n=19,584) were extracted. Cox models using time-varying covariates were implemented. Median OS for right-sided colon cancer (RCC), left-sided colon cancer, and rectal cancer was calculated using inverse probability weighting and a landmark point of 6 months after diagnosis as reference. Results: The association between PTR and OS was dependent on tumor location (P<0.05), with a higher median OS of upfront PTR versus upfront systemic therapy in Netherlands Cancer Registry (NCR) of 1.9 (95% confidence interval: 0.9-2.8), 4.3 (3.3-5.6), and 3.4 (0.6-7.6) months in RCC, left-sided colon cancer and rectal cancer, respectively. In SEER data, the difference was 6.0 (4.0-8.0), 8.0 (5.0-10.0), and 10.0 (7.0-13.0) months, respectively. Hazard plots indicate a higher hazard of death 2 to 3 months after PTR in RCC. Conclusion: Upfront PTR is associated with improved survival regardless of primary tumor location. Patients with RCC appear to have less benefit because of higher mortality during 2 to 3 months after PTR.

[1]  H. Katayama,et al.  Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Jung,et al.  Survival Benefit of Palliative Primary Tumor Resection Based on Tumor Location in Patients with Metastatic Colorectal Cancer: A Single-center Retrospective Study. , 2020, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[3]  M. Folkert,et al.  Trends in primary surgical resection and chemotherapy for metastatic colorectal cancer, 2000-2016. , 2020 .

[4]  A. Ameur,et al.  Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis , 2020, Acta oncologica.

[5]  M. Kelsh,et al.  Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis , 2019, Cancer medicine.

[6]  J. Sicklick,et al.  Synchronous metastatic colon cancer and the importance of primary tumor laterality - A National Cancer Database analysis of right- versus left-sided colon cancer. , 2019, American journal of surgery.

[7]  I. Nagtegaal,et al.  The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival , 2019, Annals of Surgical Oncology.

[8]  L. Trippa,et al.  Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications , 2019, Clinical Cancer Research.

[9]  D. Cunningham,et al.  Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis , 2019, World Journal of Surgery.

[10]  R. Weigel,et al.  The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases , 2018, Journal of Gastrointestinal Surgery.

[11]  I. Nagtegaal,et al.  An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients , 2018, International journal of cancer.

[12]  H. Friess,et al.  Meta‐analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer , 2018, The British journal of surgery.

[13]  D. Sargent,et al.  Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. , 2018, European journal of cancer.

[14]  H. Qin,et al.  Clinical significance of Fusobacterium nucleatum, epithelial–mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients , 2017, OncoTargets and therapy.

[15]  M. Weiser,et al.  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer. , 2017, Diseases of the colon and rectum.

[16]  K. Brennan,et al.  Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer , 2017, JAMA oncology.

[17]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Zhen-hai Lu,et al.  Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis , 2017, World Journal of Surgical Oncology.

[19]  L. Kao,et al.  Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer , 2017, Cancer.

[20]  S. Barni,et al.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[21]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[22]  M. Meyerson,et al.  Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location , 2016, Clinical and translational gastroenterology.

[23]  M. Koopman,et al.  Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: A nationwide population‐based propensity‐score adjusted study in the Netherlands , 2016, International journal of cancer.

[24]  K. Søreide.  Resection of asymptomatic primary tumour in unresectable stage IV colorectal cancer: time to move on from propensity matched scores to randomized controlled trials , 2016, International journal of cancer.

[25]  A. Ulrich,et al.  Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients: A Population-Based, Propensity Score-Adjusted Trend Analysis. , 2015, Annals of surgery.

[26]  J. Skibber,et al.  Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. , 2015, JAMA surgery.

[27]  E. Cotte,et al.  GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study , 2015, BMC Cancer.

[28]  C. Punt,et al.  The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG) , 2014, BMC Cancer.

[29]  J. Hanley,et al.  Avoiding blunders involving 'immortal time'. , 2014, International journal of epidemiology.

[30]  I. Nagtegaal,et al.  Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. , 2014 .

[31]  M. Koch,et al.  Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555) , 2012, BMC Cancer.

[32]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[33]  Ronald B. Geskus,et al.  ipw: An R Package for Inverse Probability Weighting , 2011 .

[34]  J. Carmichael,et al.  Outcomes of Right vs. Left Colectomy for Colon Cancer , 2011, Journal of Gastrointestinal Surgery.

[35]  C. Punt,et al.  Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature , 2011, Annals of Surgical Oncology.

[36]  H. Lippert,et al.  Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival , 2010, Diseases of the colon and rectum.

[37]  Stephen R Cole,et al.  Adjusted survival curves with inverse probability weights , 2004, Comput. Methods Programs Biomed..

[38]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[39]  G. Fontanini,et al.  Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.

[41]  Mary M. Reilly,et al.  bshazard: A Flexible Tool for Nonparametric Smoothing of the Hazard Function , 2014, R J..

[42]  Karin Haustermans,et al.  EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. , 2014, European journal of cancer.

[43]  N. Kemeny,et al.  Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.